CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on ...

We recently published a list of 12 Most Shorted Stocks in 2025. In this article, we are going to take a look at where CRISPR ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous trading day.

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Beam Therapeutics said it used a form of CRISPR called base editing to correct, in several patients, a mutation that drives a ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...

CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day. Biotech is an area that may offer your portfolio growth today and earnings ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Cathie Wood’s ARK Invest is taking advantage of the recent dip in Tesla (TSLA) stock by purchasing 9,351 shares through its ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.0, a ...